Clinical Scorecard: Impact of Pandemic Disruptions on Hepatocellular Carcinoma Monitoring in Safety-Net Healthcare Environments
At a Glance
Category
Detail
Condition
Key Mechanisms
Routine HCC surveillance recommended at 6-month intervals for patients with cirrhosis, associated with earlier tumor stage at diagnosis and improved outcomes.
Target Population
Care Setting
Key Highlights
Routine HCC surveillance is associated with earlier tumor stage at diagnosis and improved outcomes.
A meta-analysis showed only 24.0% HCC surveillance utilization among patients with cirrhosis.
COVID-19 pandemic caused a 44% decline in HCC surveillance rates among veterans with cirrhosis.
The study evaluates HCC surveillance recovery post-pandemic among vulnerable populations.
Cirrhosis diagnosis was based on ICD-10-CM codes from electronic health records.
The study focuses on understanding the rebound of HCC surveillance post-pandemic.
Guideline-Based Recommendations
Diagnosis
Management
HCC surveillance using abdominal imaging modalities such as ultrasonography, CT, or MRI, as per guidelines.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients received routine care with at least 1 healthcare encounter annually, which is crucial for HCC surveillance.
Clinical Best Practices
Ensure regular HCC surveillance for patients with cirrhosis.
Utilize appropriate imaging modalities for HCC surveillance as per guidelines.
Address barriers to timely cirrhosis care in safety-net populations, including socioeconomic factors.
by Robert J. Wong, Patricia Jones, Bolin Niu, Paulo Pinheiro, Mae Thamer, Onkar Kshirsagar, Yi Zhang, Ronnie Fass, Daniela Prieto-Bello, Lisa Quirk, George Therapondos, Amit G. Singal, Mandana Khalili
